knowledge -WSS

knowledge

author：entertainment 2025-09-06 03:56:27 - browse：196

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Padmanee Sharma of MD Anderson at center of lawsuit over credit

WSS

Texas Medical Board asked to define abortion emergency exception

Alkermes shareholders re

Peter Hotez and the public health issue of online harassment

Tori Bowie and the unacceptable rates of Black maternal death

Cano Health’s bankruptcy is a warning for Medicare Advantage

Readout Newsletter: Amgen, Regeneron, BGI Group and more

focus

knowledge

leisure time

Cancer drug shortages should be causing more outrage

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Continuity nursing helped my family in our darkest PICU moments

How to save PrEP access — and even expand it

Trump demands the U.S. pay no more for drugs than other countries … again

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

ChatGPT in medicine: STAT answers readers' burning questions

Bernie brings in new pharma CEOs to talk drug prices

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

knowledge

Problems with a popular proposal to regulate AI in health care

ChatGPT in medicine: STAT answers readers' burning questions

Unique patient identifier: Experts argue the benefits, pitfalls

A single Democrat is willing to weaken Medicare negotiation power

The high cost of giving birth even with insurance

Medicare proposal to cover medical devices draws a mixed reaction

focus

hotspot

Wikipedia

explore